Tang Capital Management AVIR Position
Active3-Fund ConvergenceTang Capital Management trimmed their position in Atea Pharmaceuticals, Inc. (AVIR) in Q4 2025, holding $17.2M worth of shares across 4,814,700 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
AVIR is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 12.8% of float with 12.6 days to cover, indicating significant bearish positioning against Tang Capital's long thesis.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Full company profile →Short Interest
12.8%
12.6 days to cover
Tang Capital Management AVIR Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 4,814,700 | -11,500 | $17.2M |
| Q3 2025 | Decreased | 4,826,200 | -63,000 | $14.0M |
| Q2 2025 | Increased | 4,889,200 | +89,200 | $17.6M |
| Q1 2025 | Increased | 4,800,000 | +11,088 | $14.4M |
| Q4 2024 | Increased | 4,788,912 | +181,852 | $16.0M |
| Q3 2024 | Increased | 4,607,060 | +130,319 | $15.4M |
| Q2 2024 | Increased | 4,476,741 | +400,000 | $14.8M |
| Q1 2024 | Held | 4,076,741 | — | $16.5M |
| Q4 2023 | Increased | 4,076,741 | +476,741 | $12.4M |
| Q3 2023 | Increased | 3,600,000 | +573,545 | $10.8M |
| Q2 2023 | Increased | 3,026,455 | +2,023,873 | $11.3M |
| Q1 2023 | New | 1,002,582 | +1,002,582 | $3.4M |
Frequently Asked Questions
Does Tang Capital Management own AVIR?
Yes. As of Q4 2025, Tang Capital Management holds 4,814,700 shares of Atea Pharmaceuticals, Inc. (AVIR) valued at $17.2M. This data comes from their SEC 13F filing.
How many hedge funds own AVIR?
3 specialist biotech hedge funds currently hold AVIR, including EcoR1 Capital, Cormorant Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy AVIR?
Tang Capital Management's position in AVIR was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's AVIR position increasing or decreasing?
Tang Capital Management trimmed their AVIR position in the most recent quarter, reducing by 11,500 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AVIRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →